Track 2 Stop 5 organ threatening disease - Systemic Lupus Erythematosus
Visit https://www.annenberg.net/SLE-CME for the complete CE/CME program. Michelle Petri, MD, MPH, and Daniel J. Wallace, MD, FACP, MACR, provide their experience and insight into the diagnosis and management of systemic lupus erythematosus (SLE), with perspectives for both general practitioners and rheumatologists.
Видео Track 2 Stop 5 organ threatening disease - Systemic Lupus Erythematosus канала Annenberg Center for Health Sciences
Видео Track 2 Stop 5 organ threatening disease - Systemic Lupus Erythematosus канала Annenberg Center for Health Sciences
Показать
Комментарии отсутствуют
Информация о видео
27 февраля 2019 г. 2:18:25
00:04:27
Другие видео канала
Clinical Cases in Interstitial Lung Disease - Case 2
Palliative Care: Pulmonary Rehabilitation - Interstitial Lung Disease: Altering the Disease Course
Melanoma: Updates from Brisbane, Australia (Abstract 4, Question 1)
Evaluation and Diagnosis: Diagnostic Algorithm for IPF - Interstitial Lung Disease
Treatment of Moderate-Severe Atopic Dermatitis: Overview
The New Paradigm in Atopic Dermatitis Treatment: Line 1 Stop 3 Disease Assessment
The New Paradigm in Atopic Dermatitis Treatment: Line 2 Stop 5 Osteoporosis
Module 3 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies
Future Directions: Telomere - Interstitial Lung Disease: Altering the Disease Course
Treatment of Moderate-Severe Atopic Dermatitis: Line 7 Stop 3 Clinical Efficacy
Understanding Biosimilars: Differences Between Biosimilars and Reference Products
Managing Challenges with Traditional Treatments: Polycythemia Vera
Treating Acute Exacerbations: Is It an Exacerbation? - Interstitial Lung Disease
The New Paradigm in Atopic Dermatitis Treatment: Line 6 Stop 3 Topical Calcineurin Inhibitors
Treatment Options (Track T Stop 2) IPF: Navigating a Complex Disease
Introduction - Combination Basal Insulin + GLP-1RA Therapy
Diagnosis Algorithm (Track H Stop 9) IPF: Navigating a Complex Disease
Future Directions: Clinical Trial Overview - Interstitial Lung Disease: Altering the Disease Course
Treatment of Moderate-Severe Atopic Dermatitis: Line 4 Stop 4 Adherence
Future Directions: IPF Net- Interstitial Lung Disease: Altering the Disease Course